Company profilePharmaceutical#72 of 1,318 in Pakistan✓ No DRAP alerts

Hamaz Pharmaceuticals (Pvt) Ltd.

Pharmaceutical company · 203 brands · 192 molecules

Ranked #70 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

203 registered products 52 pharmaceutical brands 192 distinct molecules 0 DRAP alerts

Company overview

203
registered products
52
pharmaceutical brands
192
distinct molecules
12
therapeutic classes
0
DRAP alerts

Hamaz Pharmaceuticals (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 203 product registrations across 192 distinct molecules. It is the 72nd largest registrant in Pakistan by product count, and ranks 70th of 213 in Other Beta-Lactam, Cephalosporins & Penems. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Antimalarials. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Hamaz

66 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

64
ceilings with an approval date
2
not revised in 2+ years
2024
oldest approval year
20242
202662
Longest without revision

Top molecules by brand count

Artemether5 brands
Ibuprofen5 brands
Cefotaxime4 brands
Ceftriaxone4 brands
Azithromycin4 brands
Levofloxacin4 brands
Paracetamol4 brands

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 4Antimalarials · 3Quinolone Antibacterials · 3Antihistamines For Systemic Use · 2Macrolides, Lincosamides And Streptogramins · 2Antithrombotic Agents · 1Ace Inhibitor · 1Angiotensin-Ii Antagonists, Combinations · 1Agents Against Amoebiasis And Other Protozoal Diseases · 1Beta-Lactam Antibacterials, Penicillins · 1Vitamin A, D & Combinations · 1Antiinflammatory And Antirheumatic Products · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official198 products · Rs 9.98 – Rs 130,361.68
DVAGO1 products · Rs 367.78 – Rs 367.78
Median across source: Rs 367.78

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Atco Pharma International (Pvt) Ltd holds 206 molecules not in this portfolio
Acetylsalicylic AcidAdapaleneAdapleneAlbuterolAminophyllineAmlodipine
MEDIATE PHARMACEUTICALS (PVT) LTD holds 87 molecules not in this portfolio
AlendronateAmlodipineAmpicillinAmpicillin BaseArremetherArtemether
NEUTRO PHARMA (PVT) LTD. holds 99 molecules not in this portfolio
AcetylcysteineAlbendazoleAmikacinAnastrazoleAntimonyAripiprazole

Get the full profile for Hamaz

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.